by Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff
This is a podcast on latest advances in the understanding and management of blood cancers. Here, we will bring a wide range of experts within hematologic malignancies to discuss various topics in depth. Host: Raj Chakraborty, MD from Columbia University, New York, Ashwin Kishtagari, MD, from Vanderbilt University, Nashville, and Edward Cliff, MD, from Harvard University, Boston Tweet your suggestions and feedback to @rajshekharucms @AshKishtagari @Eddie_Cliff @BloodCancerTalk
Language
🇺🇲
Publishing Since
7/8/2022
Email Addresses
1 available
Phone Numbers
0 available
March 26, 2025
<p>In this episode, we explore the emerging entity of CAR Transgenic T-cell Lymphoproliferative Neoplasms (CTTLN), a rare but important complication of CAR T-cell therapy. Dr. Piers Blombery from Peter MacCallum Cancer Center joins us to dissect two cases from the CARTITUDE-4 trial where patients developed T-cell lymphomas expressing the chimeric antigen receptor following cilta-cel treatment for multiple myeloma. As a bonus, we also briefly discussed Dr. Blombery’s paper on menin inhibitors in UBTF tandem duplicated AML. Here are the papers we discussed: </p><p>1. CTTLN cases from CARTITUDE-4: <a href="https://pubmed.ncbi.nlm.nih.gov/39938094/">https://pubmed.ncbi.nlm.nih.gov/39938094/<br></a><br></p><p>2. CTTLN case from MSKCC with insertional mutagenesis: <a href="https://pubmed.ncbi.nlm.nih.gov/39908432/">https://pubmed.ncbi.nlm.nih.gov/39908432/<br></a><br></p><p>3. Other CTTLN cases in myeloma: <br><a href="https://pubmed.ncbi.nlm.nih.gov/38865661/">https://pubmed.ncbi.nlm.nih.gov/38865661/<br></a><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8417502/">https://pmc.ncbi.nlm.nih.gov/articles/PMC8417502/<br></a><br></p><p>4. Response and resistance to menin inhibitors in UBTF tandem duplication AML: <a href="https://pubmed.ncbi.nlm.nih.gov/38924737/">https://pubmed.ncbi.nlm.nih.gov/38924737/<br></a><br></p>
March 19, 2025
<p>In this episode, we delve into the key clinically relevant abstracts in leukemia and myeloid neoplasms with Dr. Jayastu Senapati from the MD Anderson Cancer Center. Here are the links to the abstracts we discussed: </p><p><strong>Older AML: Ven+HMA vs 7+3</strong></p><p>Abstract 450: <a href="https://ash.confex.com/ash/2024/webprogram/Paper210320.html">https://ash.confex.com/ash/2024/webprogram/Paper210320.html<br></a><br></p><p>Abstract 971: <a href="https://ash.confex.com/ash/2024/webprogram/Paper202801.html">https://ash.confex.com/ash/2024/webprogram/Paper202801.html<br></a><br></p><p>Abstract 969: <a href="https://ash.confex.com/ash/2024/webprogram/Paper199267.html">https://ash.confex.com/ash/2024/webprogram/Paper199267.html<br></a><br></p><p><strong>Venetoclax resistance mechanisms<br></strong><br></p><p><a href="https://pubmed.ncbi.nlm.nih.gov/39478230/"><strong>https://pubmed.ncbi.nlm.nih.gov/39478230/<br></strong></a><br></p><p><strong>FLAG-GO vs FLAG-IDA <br></strong><br></p><p><a href="https://ashpublications.org/blood/article/144/Supplement%201/1513/532742/Gemtuzumab-Ozogamicin-Added-to-Fludarabine"><strong>https://ashpublications.org/blood/article/144/Supplement%201/1513/532742/Gemtuzumab-Ozogamicin-Added-to-Fludarabine<br></strong></a><br></p><p><strong> CPX-351:</strong> </p><p>Abstract 55: <a href="https://ash.confex.com/ash/2024/webprogram/Paper207094.html">https://ash.confex.com/ash/2024/webprogram/Paper207094.html<br></a><br></p><p>Abstract 60: <a href="https://ash.confex.com/ash/2024/webprogram/Paper200413.html">https://ash.confex.com/ash/2024/webprogram/Paper200413.html<br></a><br></p><p><strong>Menin Inhibitors <br></strong><br></p><p><a href="https://ash.confex.com/ash/2024/webprogram/Paper194384.html">Abstract 211</a> <a href="https://ash.confex.com/ash/2024/webprogram/Paper194384.html">https://ash.confex.com/ash/2024/webprogram/Paper194384.html</a></p><p>Abstract <a href="https://ash.confex.com/ash/2024/webprogram/Paper207106.html">212</a> <a href="https://ash.confex.com/ash/2024/webprogram/Paper207106.html">https://ash.confex.com/ash/2024/webprogram/Paper207106.html</a></p><p>Abstract <a href="https://ash.confex.com/ash/2024/webprogram/Paper194827.html">213</a> <a href="https://ash.confex.com/ash/2024/webprogram/Paper194827.html">https://ash.confex.com/ash/2024/webprogram/Paper194827.html</a></p><p>Abstracts <a href="https://ash.confex.com/ash/2024/webprogram/Paper198218.html">214</a> <a href="https://ash.confex.com/ash/2024/webprogram/Paper198218.html">https://ash.confex.com/ash/2024/webprogram/Paper198218.html</a></p><p>Abstract <a href="https://ash.confex.com/ash/2024/webprogram/Paper207072.html">215</a> <a href="https://ash.confex.com/ash/2024/webprogram/Paper198218.html">https://ash.confex.com/ash/2024/webprogram/Paper198218.html</a></p><p><a href="https://ash.confex.com/ash/2024/webprogram/Paper204375.html">Abstract 216</a> <a href="https://ash.confex.com/ash/2024/webprogram/Paper204375.html">https://ash.confex.com/ash/2024/webprogram/Paper204375.html</a></p><p> </p><p><strong>FLT3 inhibitors <br>Abstract 221: </strong><a href="https://ash.confex.com/ash/2024/webprogram/Paper201595.html">https://ash.confex.com/ash/2024/webprogram/Paper201595.html<br></a><br></p><p> </p><p><strong>MDS</strong></p><p> Abstract 349: <a href="https://ash.confex.com/ash/2024/webprogram/Paper194510.html">https://ash.confex.com/ash/2024/webprogram/Paper194510.html</a></p><p> </p><p><strong>ATRA in MDS: </strong> </p><p><a href="https://ash.confex.com/ash/2024/webprogram/Paper200433.html">https://ash.confex.com/ash/2024/webprogram/Paper200433.html</a> </p><p> </p>
February 12, 2025
<p>In this episode, we discuss the management of CML with Dr. Hagop Kantarjian from MD Anderson Cancer Center. Here are the key articles we discussed: </p><p> </p><p>1. ASC4FIRST RCT: Asciminib in newly diagnosed CML. </p><p><a href="https://pubmed.ncbi.nlm.nih.gov/38820078/">https://pubmed.ncbi.nlm.nih.gov/38820078/</a></p><p> </p><p>2. 5-year follow-up of ENESTnd RCT (nilotinib): </p><p><a href="https://pubmed.ncbi.nlm.nih.gov/26837842/">https://pubmed.ncbi.nlm.nih.gov/26837842/</a></p><p> </p><p>3. 10-year follow-up of ENESTnd RCT (nilotinib): </p><p><a href="https://pubmed.ncbi.nlm.nih.gov/33414482/">https://pubmed.ncbi.nlm.nih.gov/33414482/</a></p><p> </p><p>4. 10-year follow-up of CML-IV RCT (imatinib): </p><p><a href="https://pubmed.ncbi.nlm.nih.gov/25676422/">https://pubmed.ncbi.nlm.nih.gov/25676422/</a></p><p> </p><p>5. MD Anderson data on low-dose dasatinib (50 mg): </p><p><a href="https://pubmed.ncbi.nlm.nih.gov/36054032/">https://pubmed.ncbi.nlm.nih.gov/36054032/</a></p><p><a href="https://pubmed.ncbi.nlm.nih.gov/31553487/">https://pubmed.ncbi.nlm.nih.gov/31553487/</a></p><p> </p><p>6. CML: 2025 update on diagnosis, therapy, and monitoring: </p><p><a href="https://pubmed.ncbi.nlm.nih.gov/39093014/">https://pubmed.ncbi.nlm.nih.gov/39093014/</a></p><p> </p>
Bernard Marini, Anthony Perissinotti, et al.
Sam and Karine
Vinay Prasad, MD MPH
Chadi Nabhan, MD, MBA, FACP
Dr. Neil Love
American Society of Hematology
VJHemOnc
The Curbsiders Internal Medicine Podcast
NEJM Group
The Leukemia & Lymphoma Society
The Hematologist
European Hematology Association
Oncology Brothers
British Society for Haematology
JAMA Network
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at [email protected] for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.